TGFB1 and cancer: Six immune subtypes (e.g., C1: wound healing; C2: IFN-γ dominant; C3: inflammatory; C4: lymphocyte depleted; C5: immunologically quiet; C6: TGF-β-dominant) presented significantly different ORC6 expression levels in 15 types of cancers, including BRCA, LIHC, LUAD and PRAD (Supplementary Fig. 9).